Jacob Passweg
Overview
Explore the profile of Jacob Passweg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niederwieser D, Hasenclever D, Berdel W, Biemond B, Al-Ali H, Chalandon Y, et al.
Haematologica
. 2024 Aug;
110(1):68-77.
PMID: 39113672
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed...
2.
Baldomero H, Neumann D, Hamad N, Atsuta Y, Sureda A, Iida M, et al.
Best Pract Res Clin Haematol
. 2024 Aug;
37(2):101556.
PMID: 39098798
Hematopoietic cell transplantation (HCT) was developed more than 65 years ago to treat malignant blood disorders and irreversible bone marrow failures, with the aim of replacing a diseased hematopoietic system...
3.
Simeunovic H, Dickenmann M, Nabergoj M, Baldomero H, Masouridi-Levrat S, Nair G, et al.
EJHaem
. 2023 Feb;
4(1):262-265.
PMID: 36819181
Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving...
4.
Hayden P, Eikema D, de Wreede L, Koster L, Kroger N, Einsele H, et al.
Bone Marrow Transplant
. 2021 May;
56(10):2367-2381.
PMID: 33976382
The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for...
5.
Gavriilaki E, Touloumenidou T, Sakellari I, Batsis I, Mallouri D, Psomopoulos F, et al.
Thromb Haemost
. 2020 Mar;
120(4):638-646.
PMID: 32131130
Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). We hypothesized that pretransplant genetic susceptibility is evident in adult TA-TMA and further investigated the association...
6.
Giebel S, Labopin M, Czerw T, Socie G, Blaise D, Ghavamzadeh A, et al.
Eur J Cancer
. 2018 Dec;
106:212-219.
PMID: 30528805
Background: Anti-thymocyte globulin (ATG) is widely used to prevent graft-versus-host disease (GVHD) after allogeneic peripheral blood stem cell transplantation (alloPBSCT). The goal of this study was to retrospectively assess the...
7.
Baldomero H, Aljurf M, Zaidi S, Hashmi S, Ghavamzadeh A, Elhaddad A, et al.
Bone Marrow Transplant
. 2018 Aug;
54(3):402-417.
PMID: 30082852
Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in...
8.
Lorentino F, Labopin M, Bernardi M, Ciceri F, Socie G, Cornelissen J, et al.
Am J Hematol
. 2018 Jul;
93(10):1236-1244.
PMID: 30058714
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the absence...
9.
Czyz A, Labopin M, Giebel S, Socie G, Apperley J, Volin L, et al.
Am J Hematol
. 2018 Mar;
93(6):778-785.
PMID: 29574915
Allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative conditioning based on total body irradiation (TBI) is widely used for the treatment of adults with acute lymphoblastic leukemia (ALL). TBI is most...
10.
Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, et al.
Clin Infect Dis
. 2018 Feb;
67(4):564-572.
PMID: 29481599
Background: This study was performed to assess the incidence of and risk factors for Candida infection in the first 100 days after allogeneic hematopoietic stem cell transplantation (HSCT) and the...